June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
Statins and α cyclodextrin treatments prevent cholesterol crystal-induced pathology in human retinal endothelial cells and in db/db mice.
Author Affiliations & Notes
  • Sandra S Hammer
    Physiology, Michigan State University, East Lansing, Michigan, United States
  • Delaney McFarland
    Physiology, Michigan State University, East Lansing, Michigan, United States
  • George Abela
    Medicine, Michigan State University, East Lansing, Michigan, United States
  • Sergio Li Calzi
    Department of Ophthalmology and Visual Sciences School of Medicine, University of Alabama at Birmingham, Alabama, United States
  • Maria B Grant
    Department of Ophthalmology and Visual Sciences School of Medicine, University of Alabama at Birmingham, Alabama, United States
  • Julia V Busik
    Physiology, Michigan State University, East Lansing, Michigan, United States
  • Footnotes
    Commercial Relationships   Sandra Hammer, None; Delaney McFarland, None; George Abela, None; Sergio Li Calzi, None; Maria Grant, None; Julia Busik, None
  • Footnotes
    Support   F32EY028426, R01EY030766, R01EY016077
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 2928. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Sandra S Hammer, Delaney McFarland, George Abela, Sergio Li Calzi, Maria B Grant, Julia V Busik; Statins and α cyclodextrin treatments prevent cholesterol crystal-induced pathology in human retinal endothelial cells and in db/db mice.. Invest. Ophthalmol. Vis. Sci. 2021;62(8):2928.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Previous work highlights the detrimental effect elevated retinal cholesterol levels have on diabetic retinopathy (DR) progression. We have shown that downregulation of LXRα/SIRT1 results in dysregulated cholesterol metabolism and increased retinal cholesterol levels. In turn, elevated cholesterol levels lead to the formation of retinal cholesterol crystals (CC), exacerbating the pro-inflammatory and apoptotic milieu present in the diabetic retina. The focus of this study was to investigate the therapeutic potential of cholesterol lowering drugs in preventing CC-induced retinal damage in endothelial cells and in a type 2 diabetic mouse model.

Methods : Human retinal endothelial cells (HREC) were treated with CC (2mg/ml) and/or CC pretreated with Atorvastatin (10mM), Rosuvastatin (10mM), or α cyclodextrin (10mM) for 24hrs. Inflammation was measured via IL6 and IL8 levels by qRTPCR. Cell survival was determined via trypan blue exclusion assay. Type 2 diabetes was modeled in vivo via the db/db mouse model. Alpha cyclodextrin was administered three times a week for 2 weeks via subcutaneous injections (4g/kg). Cholesterol crystals were visualized using SEM and quantified using ImageJ software analysis.

Results : Pretreatment of CC with Atorvastatin, Rosuvastatin, or α cyclodextrin reduced the amount of crystals when compared to non-treated controls ex vivo. In culture, administration of CC significantly upregulated IL6 and IL8 expression (p<0.0001; n=3) in retinal endothelial cells. Treatment with Atorvastatin (p<0.05), Rosuvastatin (p<0.001), or α cyclodextrin (p<0.0001) significantly prevented CC-induced IL6 and IL8 upregulation (n=3). CC significantly increased cell death (p<0.01) after 24hrs while pretreatment with Atorvastatin, Rosuvastatin, or α cyclodextrin prevented CC-induced cell death (n=3). Lastly, long term type 2 diabetes (6 months) significantly increased the amount of retinal CC (p<0.05; n=5) while treatment with α cyclodextrin significantly reduced crystal formation in diabetic mice (p<0.01; n=3).

Conclusions : Increased retinal cholesterol levels, resulting from long term diabetes, leads to the formation of pro-inflammatory CC formation. Treatment with cholesterol lowering and/or dissolving therapeutics is an effective strategy to reduce retinal inflammation and cell death by preventing CC induced retinal damage.

This is a 2021 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×